XFOR News & Events

Reports Q4 revenue $2.6M, consensus $1.73M. "Our focus remains on our pivotal 4WARD trial in chronic neutropenia as we execute our strategy to deliver life-changing therapies to people living with rare blood diseases," said Adam Craig, M.D., Ph.D., Executive Chairman of X4 Pharmaceuticals. "We have sharpened our operational focus and implemented targeted initiatives to drive continued progress in 4WARD with enrollment on track for completion in the third quarter of this year. Additionally, we were pleased to receive the positive opinion from the European Medicines Agency recommending the potential European approval of mavorixafor in WHIM syndrome, which would be the first and only therapy in Europe to treat this devastating condition."

Cash, cash equivalents and short-term investments totaled $253.0 million as of December 31, 2025, which management believes will enable the Company to fund its operations through 2028.

X4 Pharmaceuticals announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization, under exceptional circumstances, of mavorixafor for the treatment of WHIM syndrome in the European Union. The positive opinion will now be reviewed by the European Commission with a final approval decision anticipated in the second quarter of 2026.